Literature DB >> 9299974

A laboratorian's perspective on evaluation and implementation of new laboratory tests.

D J O'Kane1, T A Ebert, B J Hallaway, S G Roberts, A K Bhuiyan, K S Tenner.   

Abstract

New assay development should be directed toward answering fundamental clinical questions. Caveats that must be considered before initiating assay development projects are: New assays should allow the clinician to interact with and treat a patient more effectively, thereby improving medical outcome; and new assays should facilitate recapture of system resources, enabling cost savings or reinvestment of resources. Defining the clinical questions and consideration of the caveats permit a means of prioritizing assay development activities. Laboratorians are faced with evaluating several types of development activities that lead to assay implementation in routine clinical testing. Assays can be prioritized for up-grading to newer cost-effective technologies, provided the changes maintain or improve analytical and clinical performance. Predicting which research assay will have future value is difficult when clinical performance is not fully validated. However, such assay development has the greatest potential for changing the delivery of healthcare by a clinician.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299974

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Selection of a suitable assay.

Authors:  Peter G Murphy
Journal:  Clin Biochem Rev       Date:  2008-08

2.  Integrating a FISH imaging system into the cytology laboratory.

Authors:  G Denice Smith; Matt Riding; Kim Oswald; Joel S Bentz
Journal:  Cytojournal       Date:  2010-04-06       Impact factor: 2.091

Review 3.  Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.

Authors:  Stephanie S Buehler; Bereneice Madison; Susan R Snyder; James H Derzon; Nancy E Cornish; Michael A Saubolle; Alice S Weissfeld; Melvin P Weinstein; Edward B Liebow; Donna M Wolk
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.